An observational study in Laryngeal Lesions and Systemic Inflammatory Process, sponsored by Antalya Health Sciences University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Antalya Health Sciences University · Observational
The aim of this study is to evaluate the levels of systemic inflammatory markers such as PIV, SII, and NPAR in patients with benign and premalignant laryngeal lesions and to determine the diagnostic accuracy of these values using ROC analysis.
Benign laryngeal lesions are generally nodules, polyps, or cysts that form due to overuse of the voice or vocal cord trauma. Reinke's edema, also within this group, is a benign laryngeal condition characterized by the accumulation of gelatinous fluid in the superficial lamina propria of the vocal cords. It is usually associated with chronic irritation, particularly smoking, and is frequently seen in middle-aged individuals with a long history of tobacco use. Previous experimental studies have shown that cigarette smoke triggers inflammatory responses in vocal cord fibroblasts and increases the production of inflammatory mediators. The cellular and systemic inflammatory processes triggered by irritation due to chronic smoking are still not fully understood. In recent years, systemic inflammation markers derived from routine hemogram parameters have attracted attention as low-cost and reliable potential biomarkers in various inflammatory and neoplastic diseases. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), hemoglobin-eosinophil ratio (HEO), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV), as well as more comprehensive indices reflecting both inflammatory and nutritional status such as Neutrophil-Albumin Ratio (NPAR) and HALP (Hemoglobin, Albumin, Platelet Ratio), are inexpensive and readily available indicators of systemic inflammation. However, a review of the literature reveals a lack of studies examining the relationship between benign and malignant laryngeal lesions and systemic inflammation through these comprehensive indices (PIV and NPAR). The aim of this study is to evaluate the levels of systemic inflammatory markers such as PIV, SII, and NPAR in patients with benign and premalignant laryngeal lesions and to determine the diagnostic accuracy of these values using ROC analysis.
Antalya Health Sciences University is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion was planned for patients aged 18 and over, with a diagnosis of vocal cord lesion via endoscopic or surgical means, and with complete blood count and albumin data in hospital records.
Exclusion Criteria:
Other: Laryngeal polyps
Other: Laryngeal nodules
Other: Laryngeal cysts
Other: Reinke's edema
Other: Papillomas
Other: Dysplasia
Other: High-risk premalignant lesions
Other: Malignant vocal cord lesions
Other: Asymptomatic smokers without vocal cord lesions
Bening laryngeal lesions
Bening laryngeal lesions
Bening laryngeal lesions
Bening laryngeal lesions
Premalign laryngeal lesions
Premalign laryngeal lesions
Premalign laryngeal lesions
Malign laryngeal lesions
None laryngeal lesions
Determining the diagnostic accuracy of PIV
PIV (pan-immune-inflammation value)
Time frame: Postoperative 1 month
Determining the diagnostic accuracy of NLR
NLR (neutrophil-lymphocyte ratio)
Time frame: Postoperative 1 month
Determining the diagnostic accuracy of PLR
PLR (platelet-lymphocyte ratio)
Time frame: Postoperative 1 month
Determining the diagnostic accuracy of HEO
HEO (hemoglobin-eosinophil ratio)
Time frame: Postoperative 1 month
Determining the diagnostic accuracy of SII
SII (systemic immune-inflammation index)
Time frame: Postoperative 1 month
Determining the diagnostic accuracy of NPAR
NPAR (neutrophil-albumin ratio)
Time frame: Postoperative 1 month
Determining the diagnostic accuracy of HALP
HALP (hemoglobin, albumin, platelet ratio)
Time frame: Postoperative 1 month
Plan to share: No
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Antalya Health Sciences University